LataMed AI Corp. (OTC: LMED), a healthcare technology company focusing on digital health and artificial intelligence for Latin America, announced on August 3, 2026, that its Venezuelan subsidiary, LATAMEDAI VE, has signed an agreement with DROGUERIAS LALA C.A. to develop AI-supported and automated software tools for pharmaceutical and laboratory workflows. This collaboration could significantly impact the pharmaceutical industry in the region by potentially improving efficiency and accuracy in research, testing, and quality control.
Under the agreement, the two companies will collaborate on designing, developing, testing, and evaluating customized technology intended to support workflows associated with pharmaceutical research, laboratory testing, quality-control processes, documentation, operational coordination, and data analysis. The proposed technology is expected to include software tools for organizing and analyzing information generated during pharmaceutical development and laboratory activities. Planned functionality may include workflow automation, testing coordination, document management, data review, quality-control support, and predictive analytical tools to help qualified personnel identify potential inconsistencies or operational issues earlier.
This partnership is strategically important because it represents LataMed AI's expansion beyond its patient-facing telemedicine services into enterprise pharmaceutical and laboratory applications. The company's management believes this initiative aligns with its broader strategy of developing digital infrastructure and AI-supported tools for healthcare providers, pharmacies, laboratories, and other ecosystem participants. If successfully developed, the technology could potentially be adapted for other organizations in Venezuela and Latin America, subject to separate agreements and regulatory requirements.
The agreement establishes a framework for collaboration but does not guarantee a specific implementation schedule, commercial deployment, or revenue. Both parties will begin by identifying specific workflows, defining technical and operational requirements, and establishing a phased development and testing process. They will also implement confidentiality, information-security, data-management, and access-control procedures.
A critical aspect of the initiative is the emphasis on professional oversight. The proposed technology is designed as a decision-support and workflow-management resource, not a replacement for professional judgment. Any pharmaceutical, scientific, laboratory, or quality-control determinations will remain the responsibility of qualified professionals and regulatory authorities. The technology would not independently approve pharmaceutical formulas, laboratory results, medical products, or regulatory submissions.
Dr. Kevin Rodan Levy, CEO of LataMed AI, stated, "This agreement represents an opportunity to apply our artificial intelligence and automation capabilities within complex pharmaceutical and laboratory environments. Our objective is to work with DROGUERIAS LALA C.A. to develop responsible technology that supports data analysis, documentation, testing coordination, quality-control processes, and other operational requirements while preserving appropriate professional oversight."
For more information, visit the company's website at https://latamed.ai or review SEC filings at www.sec.gov.
